Relationship Between Adverse Events and Microbiomes in Advanced Hepatocellular Carcinoma Patients Treated With Sorafenib.

Yamamoto, Kenta; Kuzuya, Teiji; Honda, Takashi; Ito, Takanori; Ishizu, Yoji; Nakamura, Masanao; Miyahara, Ryoji; Kawashima, Hiroki; Ishigami, Masatoshi; Fujishiro, Mitsuhiro

Yamamoto, Kenta; Kuzuya, Teiji; Honda, Takashi; Ito, Takanori; Ishizu, Yoji; Nakamura, Masanao; Miyahara, Ryoji; Kawashima, Hiroki; Ishigami, Masatoshi; Fujishiro, Mitsuhiro.

Afiliação

Yamamoto K; Department of Gastroenterology and Hepatology, Nagoya University Graduate School of Medicine, Nagoya, Japan.
Kuzuya T; Department of Gastroenterology and Hepatology, Nagoya University Graduate School of Medicine, Nagoya, Japan.
Honda T; Department of Gastroenterology and Hepatology, Nagoya University Graduate School of Medicine, Nagoya, Japan honda@med.nagoya-u.ac.jp.
Ito T; Department of Gastroenterology and Hepatology, Nagoya University Graduate School of Medicine, Nagoya, Japan.
Ishizu Y; Department of Gastroenterology and Hepatology, Nagoya University Graduate School of Medicine, Nagoya, Japan.
Nakamura M; Department of Gastroenterology and Hepatology, Nagoya University Graduate School of Medicine, Nagoya, Japan.
Miyahara R; Department of Gastroenterology and Hepatology, Nagoya University Graduate School of Medicine, Nagoya, Japan.
Kawashima H; Department of Gastroenterology and Hepatology, Nagoya University Graduate School of Medicine, Nagoya, Japan.
Ishigami M; Department of Gastroenterology and Hepatology, Nagoya University Graduate School of Medicine, Nagoya, Japan.
Fujishiro M; Department of Gastroenterology and Hepatology, Nagoya University Graduate School of Medicine, Nagoya, Japan.

Anticancer Res ; 40(2): 665-676, 2020 Feb.

Article em En | MEDLINE | ID: mdl-32014907

Assuntos

Carcinoma Hepatocelular/tratamento farmacológico; Carcinoma Hepatocelular/microbiologia; Neoplasias Hepáticas/tratamento farmacológico; Neoplasias Hepáticas/microbiologia; Microbiota; Sorafenibe/efeitos adversos; Idoso; Idoso de 80 Anos ou mais; Antineoplásicos/administração & dosagem; Antineoplásicos/efeitos adversos; Antineoplásicos/sangue; Antineoplásicos/farmacocinética; Carcinoma Hepatocelular/metabolismo; Carcinoma Hepatocelular/patologia; Feminino; Humanos; Neoplasias Hepáticas/metabolismo; Neoplasias Hepáticas/patologia; Masculino; Sorafenibe/administração & dosagem; Sorafenibe/sangue; Sorafenibe/farmacocinética

Palavras-chave

Microbiome; hepatocellular carcinoma; sorafenib; tyrosine kinase inhibitors

Texto completo

Adicionar na Minha BVS

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Carcinoma Hepatocelular / Microbiota / Sorafenibe / Neoplasias Hepáticas Limite: Aged / Aged80 / Female / Humans / Male Idioma: En Revista: Anticancer Res Ano de publicação: 2020 Tipo de documento: Article País de afiliação: Japão País de publicação: Grécia

Texto completo

Adicionar na Minha BVS

Imprimir

XML

PubMed Links

Buscar no Google